Chief Business Officer

Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress

FDA Lifts Clinical Hold, Clearing Neurizon’s ALS Drug for Human Trials

Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression

Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease

Senior/Executive Director, Program Management

Prilenia is a private biopharmaceutical company dedicated to developing transformative medicines for neurodegenerative diseases. They are seeking a Senior/Executive Director of Program Management to lead integrated program management across various development programs, providing oversight of program strategy and management while collaborating with the leadership team.

Sign up with Google

Sign in with Google